Your browser is no longer supported. Please, upgrade your browser.
ENOB Enochian Biosciences Inc. daily Stock Chart
Enochian Biosciences Inc.
Index- P/E- EPS (ttm)-0.40 Insider Own69.02% Shs Outstand32.66M Perf Week1.80%
Market Cap277.61M Forward P/E- EPS next Y- Insider Trans- Shs Float11.21M Perf Month30.77%
Income-11.20M PEG- EPS next Q- Inst Own- Short Float0.14% Perf Quarter49.12%
Sales- P/S- EPS this Y-138.80% Inst Trans- Short Ratio0.44 Perf Half Y88.89%
Book/sh4.25 P/B2.00 EPS next Y- ROA-8.80% Target Price- Perf Year78.95%
Cash/sh0.41 P/C20.72 EPS next 5Y- ROE-9.90% 52W Range3.32 - 9.50 Perf YTD21.43%
Dividend- P/FCF- EPS past 5Y-8.80% ROI- 52W High-10.53% Beta1.03
Dividend %- Quick Ratio17.30 Sales past 5Y- Gross Margin- 52W Low156.02% ATR0.55
Employees2 Current Ratio17.30 Sales Q/Q- Oper. Margin- RSI (14)57.92 Volatility8.13% 5.59%
OptionableNo Debt/Eq0.00 EPS Q/Q-273.10% Profit Margin- Rel Volume1.83 Prev Close8.80
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume35.72K Price8.50
Recom- SMA2015.24% SMA5017.21% SMA20050.93% Volume63,667 Change-3.41%
Jan-16-19 04:00PM  OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire +10.00%
Jan-07-19 08:30AM  Enochian Biosciences Announces Appointment of Dr. Mark Dybul as Executive Vice-Chair GlobeNewswire
Jan-04-19 08:00AM  How Much Of Enochian Biosciences Inc. (NASDAQ:ENOB) Do Insiders Own? Simply Wall St.
Dec-05-18 08:30AM  Enochian Biosciences Announces Uplisting to Nasdaq Under Symbol ENOB GlobeNewswire
Dec-03-18 08:30AM  Enochian Biosciences to Present at Biotech Showcase 2019 GlobeNewswire
Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.